stockportfolio.pro
NTRA vs RMD: Which Stock Is the Better Buy?
Natera, Inc. and ResMed Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — NTRA vs RMD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Natera, Inc. (NTRA) | ResMed Inc. (RMD) | |
|---|---|---|
| Market cap | $31.0B | $30.4B |
| Revenue (latest FY) | $2.31B | $5.15B |
| Net income (latest FY) | $-208.16M | $1.40B |
| Revenue growth (5y CAGR) | 42.6% | 11.7% |
| Net margin | -9.0% | 27.2% |
| Return on equity | -12.2% | 23.5% |
| P/E ratio | — | 20.2 |
| Dividend yield | — | 1.1% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | Yes | Yes |
See the full NTRA vs RMD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open NTRA's full financials → Open RMD's full financials →More comparisons
Frequently asked questions
Which is bigger, NTRA or RMD?
Natera, Inc. is larger by market capitalization — $31.0B versus $30.4B.
Which grows faster, NTRA or RMD?
Over the last five fiscal years, Natera, Inc. grew revenue faster — 42.6%/yr versus 11.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.